rhi002 and Autoimmune-Diseases-of-the-Nervous-System

rhi002 has been researched along with Autoimmune-Diseases-of-the-Nervous-System* in 1 studies

Other Studies

1 other study(ies) available for rhi002 and Autoimmune-Diseases-of-the-Nervous-System

Article	Year
Identification of two HIV inhibitors that also inhibit human RNaseH2. Molecules and cells, 2013, Volume: 36, Issue:3 A total of 140,000 compounds were screened in a targetfree cell-based high throughput assay against HIV-1 infection, and a subset of 81 promising compounds was identified. Secondary screening of these 81 compounds revealed two putative human RNaseH2 inhibitors, RHI001 and RHI002, with IC50 value of 6.8 μM and 16 μM, respectively. RHI002 showed selective activity against human RNaseH2 while RHI001 inhibited HIV-RNaseH, E. coli RNaseH, and human RNaseH1 with IC50 value of 28.5 μM, 7.9 μM, and 31.7 μM, respectively. Kinetic analysis revealed that both inhibitors had non-competitive inhibitor-like properties. Because RNaseH2 is involved in the etiology of Aicardi-Goutier syndrome and has been suggested as an anticancer drug target, small molecule inhibitors modulating its activity would be useful for investigating the cellular function of this molecule. Topics: Anti-HIV Agents; Autoimmune Diseases of the Nervous System; Cell Line, Tumor; Drug Evaluation, Preclinical; Enzyme Inhibitors; Escherichia coli Proteins; HeLa Cells; High-Throughput Screening Assays; HIV-1; Humans; Molecular Structure; Nervous System Malformations; Pyrimidines; Ribonuclease H; Ribonuclease H, Human Immunodeficiency Virus; Ribonucleases; Thiophenes	2013

Article

Year

Identification of two HIV inhibitors that also inhibit human RNaseH2.

Molecules and cells, 2013, Volume: 36, Issue:3

A total of 140,000 compounds were screened in a targetfree cell-based high throughput assay against HIV-1 infection, and a subset of 81 promising compounds was identified. Secondary screening of these 81 compounds revealed two putative human RNaseH2 inhibitors, RHI001 and RHI002, with IC50 value of 6.8 μM and 16 μM, respectively. RHI002 showed selective activity against human RNaseH2 while RHI001 inhibited HIV-RNaseH, E. coli RNaseH, and human RNaseH1 with IC50 value of 28.5 μM, 7.9 μM, and 31.7 μM, respectively. Kinetic analysis revealed that both inhibitors had non-competitive inhibitor-like properties. Because RNaseH2 is involved in the etiology of Aicardi-Goutier syndrome and has been suggested as an anticancer drug target, small molecule inhibitors modulating its activity would be useful for investigating the cellular function of this molecule.

Topics: Anti-HIV Agents; Autoimmune Diseases of the Nervous System; Cell Line, Tumor; Drug Evaluation, Preclinical; Enzyme Inhibitors; Escherichia coli Proteins; HeLa Cells; High-Throughput Screening Assays; HIV-1; Humans; Molecular Structure; Nervous System Malformations; Pyrimidines; Ribonuclease H; Ribonuclease H, Human Immunodeficiency Virus; Ribonucleases; Thiophenes

2013